ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2011
Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01696539 (Pilot Intervention Study of the Impact of Sustainable Daily Physical Activity on Health and Quality of Life in a Cohort of Men With Prostate Cancer in Sweden), which is not on this map. Cited by 70 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pilot Intervention Study of the Impact of Sustainable Daily Physical Activity on Health and Quality of Life in a Cohort of Men With Prostate Cancer in Sweden: Steps for PRosTAte Cancer Health and Survival (SPaRTACuS)
Who cites it
70 citing papers in PubMed, 2 syntheses or guidelines pooled it, 145 citations in OpenAlex.
- Benefits of weight loss programs for breast cancer survivors: a systematic reviews and meta-analysis of randomized controlled trials.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Pooled it
- Impact of body mass index on pathological complete response following neoadjuvant chemotherapy in operable breast cancer: a meta-analysis.Breast cancer (Tokyo, Japan) · 2021Pooled it
- "Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study".BMC cancer · 2021Trial
- Hemoglobin A1c Levels Modify Associations between Dietary Acid Load and Breast Cancer Recurrence.Nutrients · 2020Trial
- Consumption of Fresh Yellow Onion Ameliorates Hyperglycemia and Insulin Resistance in Breast Cancer Patients During Doxorubicin-Based Chemotherapy: A Randomized Controlled Clinical Trial.Integrative cancer therapies · 2017Trial
- Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Trial
- Impact of Body Weight Loss During Preoperative Chemoradiotherapy on Prognosis of Patients With Lower Rectal Cancer.Annals of gastroenterological surgery · 2026Article
- Dissecting lncRNA-mRNA regulatory network in type 2 diabetes as the risk factor of pancreatic cancer.Scientific reports · 2025Article
- Exercise and cardiovascular health among breast cancer survivors: a scoping review of current observational evidence.Cardio-oncology (London, England) · 2025Review
- Insulin Resistance: The Increased Risk of Cancers.Current oncology (Toronto, Ont.) · 2024Review
- The association of serum C-peptide with the risk of cardiovascular events: a meta-analysis and systematic review.Diabetology & metabolic syndrome · 2023Review
- Normative range of various serum hormonal parameters among Indian women of reproductive age: ICMR-PCOS task force study outcome.The Lancet regional health. Southeast Asia · 2023Article
- Article
- The Predictive Importance of Body Mass Index on Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer.Breast care (Basel, Switzerland) · 2023Article
- Serum C-peptide level and the risk of cardiovascular diseases mortality and all-cause mortality: a meta-analysis and systematic review.Frontiers in cardiovascular medicine · 2023Review
- The bidirectional association of C-peptide with cardiovascular risk in nondiabetic adults and patients with newly diagnosed type 2 diabetes mellitus: a retrospective cohort study.Cardiovascular diabetology · 2022Article
- Obesity, cancer risk, and time-restricted eating.Cancer metastasis reviews · 2022Review
- Insulin resistance and weight gain in women treated for early stage breast cancer.Breast cancer research and treatment · 2022Observational
- An Overview of the Impact of Body Mass Index on Pathological Complete Response Following Neoadjuvant Chemotherapy in Operable Breast Cancer in a Tertiary Care Centre in South India.European journal of breast health · 2022Article
- Insulin Resistance and Cancer: In Search for a Causal Link.International journal of molecular sciences · 2021Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
purposeTo examine the association between serum C-peptide, a marker of insulin secretion, measured 3 years after a breast cancer diagnosis, and death resulting from all causes and breast cancer. PATIENTS AND
methodsThis was a prospective, observational study of 604 women enrolled onto the Health, Eating, Activity, and Lifestyle (HEAL) Study who were diagnosed with local or regional breast cancer between 1995 and 1998 and observed until death or December 31, 2006, whichever came first. The hazard ratio (HR) for all deaths and deaths owing to breast cancer and 95% CIs for the HR were estimated using multivariable stratified Cox regression analyses.
resultsAmong women without type 2 diabetes, fasting C-peptide levels were associated with an increased risk of death resulting from all causes and from breast cancer. A 1-ng/mL increase in C-peptide was associated with a 31% increased risk of any death (HR = 1.31; 95% CI, 1.06 to 1.63; P = .013) and a 35% increased risk of death as a result of breast cancer (HR = 1.35; 95% CI, 1.02 to 1.87, P = .048). Associations between C-peptide levels and death as a result of breast cancer were stronger in certain subgroups, including women with type 2 diabetes, women with a body mass index less than 25 kg/m(2), women diagnosed with a higher stage of disease, and women whose tumors were estrogen receptor positive.
conclusionTreatment strategies to reduce C-peptide levels in patients with breast cancer, including dietary-induced weight loss, physical activity, and/or use of insulin-lowering medications, should be explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.